Cargando…
5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients
5‐Hydroxymethylcytosine (5hmC) is a DNA modification that is generated by the oxidation of 5‐methylcytosine (5mC) in a reaction catalyzed by the ten‐eleven translocation (TET) family enzymes. It tends to mark gene activation and affects a spectrum of developmental and disease‐related biological proc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484304/ https://www.ncbi.nlm.nih.gov/pubmed/30912288 http://dx.doi.org/10.1111/jcmm.14252 |
_version_ | 1783414097476321280 |
---|---|
author | Gao, Pingting Lin, Shengli Cai, Mingyan Zhu, Yan Song, Yanqun Sui, Yi Lin, Jing Liu, Jiaxiuyu Lu, Xingyu Zhong, Yunshi Cui, Yuehong Zhou, Pinghong |
author_facet | Gao, Pingting Lin, Shengli Cai, Mingyan Zhu, Yan Song, Yanqun Sui, Yi Lin, Jing Liu, Jiaxiuyu Lu, Xingyu Zhong, Yunshi Cui, Yuehong Zhou, Pinghong |
author_sort | Gao, Pingting |
collection | PubMed |
description | 5‐Hydroxymethylcytosine (5hmC) is a DNA modification that is generated by the oxidation of 5‐methylcytosine (5mC) in a reaction catalyzed by the ten‐eleven translocation (TET) family enzymes. It tends to mark gene activation and affects a spectrum of developmental and disease‐related biological processes. In this manuscript, we present a 5hmC selective chemical labelling technology (hmC‐Seal) to capture and sequence 5hmC‐containing DNA fragments with low input. We tested 10 tumour/adjacent colon cancer tissues and 10 tumour/healthy plasma samples. Furthermore, we tested if this methodology could generate the 5hmC differential genes among cancer patients, healthy controls and precancerous adenoma patients from plasma. Robust cancer‐specific epigenetic signatures were identified for colon cancers. The results show that 5hmC is mainly distributed in gene active regions. The results also indicate the potential application of 5hmC change signals in early stage of colon cancer, even show potential in the diagnosis of precancerous adenoma. We demonstrated the robustness of the 5hmC‐Seal method in tissue and cell‐free DNA (cfDNA) as potential biomarkers. Moreover, this study provides the potential value and feasibility of 5hmC‐Seal approach on colorectal cancer (CRC) early detection. We believe this strategy could be an effective liquid biopsy‐based diagnosis and a potential prognosis method for colon cancer using cfDNA. |
format | Online Article Text |
id | pubmed-6484304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64843042019-05-03 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients Gao, Pingting Lin, Shengli Cai, Mingyan Zhu, Yan Song, Yanqun Sui, Yi Lin, Jing Liu, Jiaxiuyu Lu, Xingyu Zhong, Yunshi Cui, Yuehong Zhou, Pinghong J Cell Mol Med Original Articles 5‐Hydroxymethylcytosine (5hmC) is a DNA modification that is generated by the oxidation of 5‐methylcytosine (5mC) in a reaction catalyzed by the ten‐eleven translocation (TET) family enzymes. It tends to mark gene activation and affects a spectrum of developmental and disease‐related biological processes. In this manuscript, we present a 5hmC selective chemical labelling technology (hmC‐Seal) to capture and sequence 5hmC‐containing DNA fragments with low input. We tested 10 tumour/adjacent colon cancer tissues and 10 tumour/healthy plasma samples. Furthermore, we tested if this methodology could generate the 5hmC differential genes among cancer patients, healthy controls and precancerous adenoma patients from plasma. Robust cancer‐specific epigenetic signatures were identified for colon cancers. The results show that 5hmC is mainly distributed in gene active regions. The results also indicate the potential application of 5hmC change signals in early stage of colon cancer, even show potential in the diagnosis of precancerous adenoma. We demonstrated the robustness of the 5hmC‐Seal method in tissue and cell‐free DNA (cfDNA) as potential biomarkers. Moreover, this study provides the potential value and feasibility of 5hmC‐Seal approach on colorectal cancer (CRC) early detection. We believe this strategy could be an effective liquid biopsy‐based diagnosis and a potential prognosis method for colon cancer using cfDNA. John Wiley and Sons Inc. 2019-03-26 2019-05 /pmc/articles/PMC6484304/ /pubmed/30912288 http://dx.doi.org/10.1111/jcmm.14252 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Gao, Pingting Lin, Shengli Cai, Mingyan Zhu, Yan Song, Yanqun Sui, Yi Lin, Jing Liu, Jiaxiuyu Lu, Xingyu Zhong, Yunshi Cui, Yuehong Zhou, Pinghong 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title | 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title_full | 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title_fullStr | 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title_full_unstemmed | 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title_short | 5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients |
title_sort | 5‐hydroxymethylcytosine profiling from genomic and cell‐free dna for colorectal cancers patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484304/ https://www.ncbi.nlm.nih.gov/pubmed/30912288 http://dx.doi.org/10.1111/jcmm.14252 |
work_keys_str_mv | AT gaopingting 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT linshengli 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT caimingyan 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT zhuyan 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT songyanqun 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT suiyi 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT linjing 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT liujiaxiuyu 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT luxingyu 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT zhongyunshi 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT cuiyuehong 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients AT zhoupinghong 5hydroxymethylcytosineprofilingfromgenomicandcellfreednaforcolorectalcancerspatients |